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Abstract
Published data on the first 5,000 coronavirus patients to receive plasma
shows promise in the United States. However, delivering convalescent
plasma therapies in low- and even middle-income countries is both difficult
and costly. Here we discuss the advantages and disadvantages of antisera
raised in animals that may allow poorer countries to control the devastating
effects of COVID-19.
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ment by Wellcome.
In a recent editorial published March 27th, Roback and Guarner 
discuss the possibilities and challenges of using human conva-
lescent plasma to treat Covid-191,2. Although we wholeheartedly 
agree with their conclusions, they fail to consider the comple-
mentary merits of using larger domesticated animals to generate 
similar clinical benefits, that avoid the considerable regulatory 
and logistical hurdles arising from the use of human donors.
While showing recent clinical promise and near immediate 
availability1,2, human convalescent plasma is expensive and 
time consuming to process due to the need to screen for human 
pathogens and requires the identification of donors with high 
neutralising anti-SARS-CoV-2 titres. At the time of writing a 
routine diagnostic to detect hyper-immune individuals is still not 
routinely available, while generating large amounts of product 
to satiate current clinical demand may not even be possible, as 
manufacturers with the skills to make enriched antisera to scale 
will still need capacity to generate other plasma therapies for 
equally pressing diseases, e.g. IVIg for the routine treatment 
of neurological disease.
In lower middle- and low-income countries (LMICs and LICs), 
plasma products are expensive and often scarce, due to lack of 
import from higher-income countries, insufficient local supply 
of plasma, and lack of infrastructure to establish plasma 
manufacturing capacity3. These factors contribute to the poor 
availability of human convalescent plasma in LMICs and 
LICs where deaths from COVID-19 are likely to be very 
substantial indeed4. While human convalescent sera may not 
be readily available in outbreak situations, antisera of animal 
origin containing high titres of neutralising antibody can be 
produced in 2-4 months. Animal-origin purified IgG and IgG 
fragment preparations are still routinely used as antivenoms5, 
and even though immunization of horses with inactivated 
Ebola virus (EBOV) failed to yield effective therapeutic 
antisera, equine hyperimmune sera produced using EBOV 
virus-like particles conferred protection against lethal challenge 
in rodents6. That antisera generated in horses can potently 
neutralise SARS-CoV-2 in vitro has also recently been observed7.
Until a reliable vaccine or therapeutic intervention becomes 
available, for LMICs and LICs, we therefore advocate immu-
nisation of larger animals, e.g. horses and sheep, such as is 
already the standard to generate antivenoms, anti-toxins, and 
anti-rabies therapeutics for human use. The polyclonal nature 
of antisera raised in animals makes it particularly suited to neu-
tralising multiple antigens, toxins and enzymes that in humans 
bitten by snakes cause coagulopathies that are also observed in 
COVID-19 patients8,9. The animal approach is still used today 
in the treatment of diphtheria, a potentially fatal respiratory 
disease caused by a toxin-producing bacterium Corynebacterium 
diphtheriae. The method, which harvests antibody-rich serum 
after injecting the diphtheria toxin into horses may appear 
antiquated, but it nonetheless saves lives10.
Furthermore, as equine and ovine hyper-immune serums are 
already licensed therapies routinely used throughout the world, 
including Europe and North America, we suggest there would 
be less of a requirement for time-consuming phase 1 safety test-
ing, as there is already a reasonable, although clearly not perfect, 
safety profile for animal derived immune sera administered 
through the i.v. route to critically sick patients11,12. A recent 
publication that domesticated cats are highly susceptible to 
SARS-CoV-2 may also favour approaches to develop antisera in 
animals for their protection and treatment13.
Although animal derived immunoglobulins provide effective 
treatments for the aforementioned indications, consideration 
must be given to the safety of such therapeutics. Intravenous 
administration of animal derived immunoglobulins is associ-
ated with the development of early and delayed (5 – 14 days post 
administration) adverse reactions, known as serum sickness. 
The incidence of adverse reactions to animal immunoglobulins 
shows great variation between products (from 3% to 88%) and is 
heavily influenced by quality of manufacturing processes and 
physicochemical properties of immunoglobulins. Early adverse 
reactions are often mild (typically, pruritis, urticaria, mild 
gastrointestinal disturbances), but can on occasion lead to life-
threatening anaphylaxis. Serum sickness also occurs with intrave-
nously administered human immunoglobulins14; and is typically 
a mild condition that only becomes clinically life-threatening 
when doses of immunoglobulins are administered on multiple 
occasions, at high dosages, or over prolonged periods of time14. 
During a one-off infusion, early adverse reactions and subsequent 
serum sickness can be carefully monitored and pharmacologi-
cally controlled15. Nevertheless, these routinely manageable early 
and delayed reactions may be a risk worth taking over the 
alternative currently unmanageable and, unfortunately, frequently 
fatal severe SARS-CoV-2 infection.
The recent excitement and potential usefulness of convalescent 
hyper-immune IgG must however be tempered by observations 
that anti-SARS-CoV-1 antibodies can contribute to severe acute 
lung injury16. This has been shown to occur through productive 
engagement of FcγRs expressed by alveolar macrophages that 
induce cytokine storms leading to Acute Respiratory Distress 
Syndrome (ARDS16). Animal derived IgG most likely do not opti-
mally engage functional in vivo responses from human FcγRs 
and may yet turn out to be superior to human convalescent IgG 
for the short-term treatment of patients with ARDS.
Mitigation of adverse reactions can also be controlled during 
product development. For example, enzymatic cleavage of 
neutralising IgG into F(ab’)2, or removal of N-linked glycans 
from the Fc, are tried and tested approaches to limit interactions 
with human immune receptors that may give rise to the observed 
adverse events associated with injected antibodies17,18. Other 
options currently being investigated include using cattle trans-
genic for human immunoglobulin genes and glycosylation human-
ised pigs, but scaling-up manufacture from the limited animals 
available (difficult to breed) from single for profit companies 
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would appear insurmountable in the short term to satisfy 
escalating demand in LICs and LMICs.
Although the use of animals in medicine has fallen out of 
favour with the general public, the scale of the current crisis 
requires a multi-pronged approach that will inevitably involve 
the holistic and complementary use of animals to control 
SARS-CoV-2 and future emerging viruses that affect both 
humans and the animals they live with.
Data availability
No data is associated with this article.
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